Strategic Initiative: First U.S. ANDA Submission
Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths. This submission represents a significant milestone in extending the company's established API and CDMO expertise into integrated finished dosage development and regulatory filing capabilities.
Product and Technical Details
The Sitagliptin program encompasses comprehensive development activities including:
- Formulation development and scale-up
- Analytical method development and validation
- Impurity control
- Stability studies
- Manufacture of regulatory batches under GMP systems
- Bioequivalence strategy development
- Coordination with contract research organizations
- Integration of development and study data into regulatory dossier
Market Context and Opportunity
Sitagliptin is an established oral treatment for adults with Type 2 diabetes, belonging to the DPP-4 inhibitor class (gliptins). The innovator product, Januvia, recorded worldwide sales of approximately US$1.604 billion in 2025 according to Merck's 2025 Annual Report.
Patent status: The relevant U.S. sitagliptin phosphate salt patent is scheduled to expire on 24th November 2026, with associated paediatric exclusivity extending to 24th May 2027. Certain manufacturers have separate arrangements permitting earlier entry.
Regulatory Timeline and Requirements
The company estimates 24–36 months from submission to progress towards approval and commercial supply, subject to:
- FDA review process
- Satisfactory completion of applicable formulation facility inspection requirements
- Applicable patent and exclusivity requirements
ANDA No. 221758 was submitted on 25th September 2026. Submission does not constitute FDA acceptance for substantive review, product approval or authorization for U.S. commercial supply.
Strategic Implications and Future Plans
This submission strengthens Morepen's ability to support specialized CDMO assignments spanning API development, finished dosage formulation and regulatory submission, broadening the scope and complexity of customer programs the company can undertake.
Future development plans include:
- Customer development programs
- Technology transfer opportunities
- Co-development arrangements
- Licensing opportunities
- Product and dossier development for regulated markets across Europe and Asia
- Exploration of differentiated formulations, including potential U.S. 505(b)(2) development programs (subject to product-specific studies and regulatory requirements)
Management Commentary
Mr. Sanjay Suri, Managing Director, Morepen Laboratories Limited stated: "Capability building is central to Morepen's next phase of growth. Our first ANDA submission brings together the scientific, manufacturing and regulatory skills needed to take an API through finished dosage development to a U.S. filing."
He further added: "Alongside our planned Innovation Hub and investments in advanced chemistry and technology, this milestone strengthens our ability to undertake specialized CDMO assignments and build long-term development partnerships."
Risk Factors and Forward-looking Statements
The release contains forward-looking statements concerning Morepen's development plans, proposed capabilities, potential partnerships, regulatory timelines and commercialization. These statements reflect current expectations and are subject to risks and uncertainties including regulatory outcomes, facility inspections, development results, intellectual property requirements and market conditions. Actual outcomes may differ materially.
Company Background
Morepen Laboratories Limited is an Indian pharmaceutical company with established expertise in active pharmaceutical ingredients and a growing focus on contract development and manufacturing. The company is expanding its scientific, manufacturing and regulatory capabilities to support integrated development programs and long-term partnerships with global pharmaceutical customers.